Thor Medical Past Earnings Performance
Past criteria checks 0/6
Thor Medical's earnings have been declining at an average annual rate of -573.1%, while the Biotechs industry saw earnings growing at 7.7% annually.
Key information
-573.1%
Earnings growth rate
n/a
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | n/a |
| Return on equity | -7.1% |
| Net Margin | n/a |
| Next Earnings Update | 26 Feb 2025 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Thor Medical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -19 | 8 | 0 |
| 31 Mar 24 | 0 | -12 | 5 | 0 |
| 31 Dec 23 | 0 | -6 | 3 | 0 |
Quality Earnings: 8NN is currently unprofitable.
Growing Profit Margin: 8NN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if 8NN's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare 8NN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 8NN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: 8NN has a negative Return on Equity (-7.14%), as it is currently unprofitable.